stockportfolio.pro
Janux Therapeutics, Inc. (JANX)
Healthcare · Biotechnology · NasdaqGM
Janux Therapeutics, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $3.64M | $8.61M | $8.08M | $10.59M | $10.00M |
| Gross profit | — | — | — | — | — | — |
| Net income | $-6.78M | $-32.67M | $-63.06M | $-58.29M | $-68.99M | $-113.63M |
| Net margin | — | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
Source: Janux Therapeutics, Inc. SEC filings (10-K).
Explore 6 years of Janux Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track JANX in your portfolio →
Janux Therapeutics, Inc. financial history by metric
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Janux Therapeutics, Inc. — frequently asked questions
What is Janux Therapeutics, Inc.'s revenue?
Janux Therapeutics, Inc. (JANX) reported revenue of $10.00M for fiscal year 2025, down 5.6% from the prior year, according to its SEC filings.
Is Janux Therapeutics, Inc. profitable?
No — JANX reported a net loss of $-113.63M in fiscal 2025.
What is JANX's P/E ratio?
Janux Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Janux Therapeutics, Inc. have?
As of fiscal year 2025, JANX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Janux Therapeutics, Inc.'s market cap?
Janux Therapeutics, Inc. (JANX) has a market capitalization of about $830.30M, based on the latest data in our nightly-refreshed cache.
When does Janux Therapeutics, Inc.'s fiscal year end?
JANX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Janux Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.